Expanding vs reserving exclusivity debated at 'Cures' hearing
This article was originally published in Scrip
Executive Summary
The 5,000-plus drugs under development in the US are evidence the current system for driving innovation is successful, and therefore, incentives like additional exclusivity protection should be reserved for true advances, said Dr Steven Miller, senior vice president and chief medical officer at Express Scripts.